Drug
H-101 clinical trials
Also written H101.
- studies test it
- 14
- open now
- 7
- in phase 3
- 2
- first study started
- 2016
Keep track of what changes. Save the H-101 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
- Phase 3
- 2
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 14
Fudan University (4) · Liu Zi (1) · Jun Huang (1) · The First Affiliated Hospital of Bengbu Medical University (1) · West China Hospital (1) · Beijing Tsinghua Chang Gung Hospital (1) · Fujian Cancer Hospital (1) · Zhejiang Cancer Hospital (1)
Often tested with
Tested in the same studies.
Camrelizumab (2) · Lenvatinib (2) · Tislelizumab (2) · Antineoplastic Agents (1) · Toripalimab (1) · Oxaliplatin (1) · Fluorouracil (1) · Leucovorin (1)
Studies
Open first, then newest update. How each study uses H-101 is read from its arms, and is right about nine times in ten.
Testing it · 14
- H101 Plus TACE for r/m HNSCCRecruitingPhase 2West China HospitalNCT07398664Written as H101
- Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLMNot yet recruitingPhase 2Jun HuangNCT07381309Written as H101
- Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic CancerNot yet recruitingPhase 2Fudan UniversityNCT06196671Written as H101
- Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)Not yet recruitingPhase 2Fudan UniversityNCT06919848Written as H101
- Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingPhase 2The First Affiliated Hospital of Bengbu Medical UniversityNCT06253598Written as Recombinant Human Adenovirus Type 5
- Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic CholangiocarcinomaRecruitingPhase 4Beijing Tsinghua Chang Gung HospitalNCT05124002Written as Recombinant Human Adenovirus Type 5
- Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung CancerRecruitingPhase 1/2Fujian Cancer HospitalNCT06136910Written as Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
- Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological MalignanciesActive, not recruitingPhase 2Liu ZiNCT05051696Written as H101
- Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant AscitesStatus unknownPhase 1Fudan UniversityNCT05303844Written as H101
- Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant AscitesCompletedPhase 2Fudan UniversityNCT04771676Written as Oncorine (H101)
- Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder CancerStatus unknownPhase 2Zhejiang Cancer HospitalNCT05564897Written as H101, Camrelizumab
- HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-BStatus unknownPhase 3Sun Yat-sen UniversityNCT03780049Written as H101
- Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.Status unknownNot applicableSouthwest Hospital, ChinaNCT03790059Written as H101
- Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC PatientsStatus unknownPhase 3Xinqiao Hospital of ChongqingNCT02579564Written as Oncorine
Given in every arm · 3 — H-101 is usual care beside what is tested
- Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)RecruitingPhase 2Fudan UniversityNCT05823987Written as H101
- Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingPhase 1Fudan UniversityNCT05675462Written as Oncorine
- Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients with Advanced Pancreatic CancerCompletedPhase 1Fudan UniversityNCT05303090Written as H101
Codes
What other systems call H-101 · ClinicalTrials.gg INT017686
- UNII (FDA) QH36X20ODGH-101One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QH36X20ODG | H-101 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.